Compounds and uses thereof for the modulation of hemoglobin
Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.
1. A compound of formula (II):
or a tautomer thereof, or a pharmaceutically acceptable salt of each thereof, wherein
ring A is a 4-10 membered heterocycle containing up to 5 ring heteroatoms, wherein each heteroatom is independently selected from the group consisting of O, N, S, and oxidized forms of N and S, the heterocycle is saturated or contains one double bond, and the heterocycle is optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from halo, C 1 -C 6 alkyl, and COOR 16 , wherein R 16 is hydrogen or C 1 -C 6 alkyl;
ring B is a phenyl or 5 or 6 membered heteroaryl having 1-3 nitrogen atoms, or oxidized versions thereof, wherein the phenyl or heteroaryl is optionally substituted with 1-3 substituents independently selected from the group consisting of halo, C 1 -C 6 alkyl, COR 15 , and COOR 15 ;
wherein R 15 is C 1 -C 6 alkyl optionally substituted with halo;
is a single or a double bond;
each Y and Z is independently CR 10 R 11 , O, S, SO, or SO 2 ; each R 10 and R 11 independently is hydrogen or C 1 -C3 alkyl optionally substituted with halo, OH, or C 1 -C 6 alkoxy, or CR 10 R 11 is C═O; provided that if one of Y and Z is O, S, SO, or SO 2 , then the other is not C═O, and provided that Y and Z are not both heteroatoms or oxidized forms thereof;
R 5 is hydrogen or C 1 -C 6 alkyl, wherein the C1-C 6 alkyl is optionally substituted with 1-5 halo;
R 6 is halo, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 alkylthio, C 1 -C 6 alkyl-S(O)—, or C 1 -C 6 alkyl-S(O) 2 —,
wherein the C 1 -C 6 alkyl is optionally substituted with 1-5 halo; and
p is 0, 1, 2, or 3.
2. The compound of claim 1 , or a tautomer thereof, or a pharmaceutically acceptable salt of each thereof, wherein p is 0.
3. The compound of claim 1 , or a tautomer thereof, or a pharmaceutically acceptable salt of each thereof,
wherein
R 6 is halo; and
p is 1.
4. A compound of Formula (IIA):
or a tautomer thereof, or a pharmaceutically acceptable salt of each thereof,
wherein
ring A is a 4-10 membered heterocycle containing up to 5 ring heteroatoms, wherein each heteroatom is independently selected from the group consisting of O, N, and S, the heterocycle is saturated or contains one double bond, and the heterocycle is optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from halo, C 1 -C 6 alkyl, and COOR 16 , wherein R 16 is hydrogen or C 1 -C 6 alkyl;
ring B is phenyl or 5 or 6 membered heteroaryl having 1-3 nitrogen atoms, wherein the phenyl or heteroaryl is optionally substituted with 1-3 substituents independently selected from the group consisting of halo, C 1 -C 6 alkyl, COR 15 , and COOR 15 ; wherein R 15 is C 1 -C 6 alkyl optionally substituted with halo;
is a single or a double bond;
R 5 is hydrogen or C 1 -C 6 alkyl, wherein the C 1 -C 6 alkyl is optionally substituted with 1-5 halo;
R 6 is halo, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 alkylthio, C 1 -C 6 alkyl-S(O)—, or C 1 -C 6 alkyl-S(O) 2 —,
wherein the C 1 -C 6 alkyl is optionally substituted with 1-5 halo; and
p is 0, 1, 2, or 3.
5. The compound of claim 4 , or a tautomer thereof, or a pharmaceutically acceptable salt of each thereof, wherein ring A is optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halo and C 1 -C 6 alkyl.
6. The compound of claim 4 , or a tautomer thereof, or a pharmaceutically acceptable salt of each thereof, wherein ring B is pyridinyl optionally substituted with one substituent selected from the group consisting of halo, C 1 -C 6 alkyl, COR 15 , and COOR 15 ; wherein R 15 is C 1 -C 6 alkyl.
7. The compound of claim 1 , wherein the compound is selected from the group consisting of
or an N oxide thereof, or a tautomer thereof, or a pharmaceutically acceptable salt of each thereof, wherein
R 14 is C 1 -C 6 alkyl;
x is 0, 1, or 2; and
m is 0, 1, or 2.
8. A compound selected from the group consisting of:
or a tautomer thereof, or a pharmaceutically acceptable salt of each thereof.
9. A pharmaceutical composition comprising a compound of claim 1 , or a tautomer thereof, or a pharmaceutically acceptable salt of each thereof, and at least one pharmaceutically acceptable excipient.
10. A method for increasing oxygen affinity of hemoglobin S in a subject, the method comprising administering to a subject in need thereof a compound of claim 1 , or a tautomer thereof, or a pharmaceutically acceptable salt of each thereof.
11. A method for treating sickle cell disease, the method comprising administering to a subject in need thereof a compound of claim 1 , or a tautomer thereof, or a pharmaceutically acceptable salt of each thereof.
12. The compound of claim 1 , or a tautomer thereof, or a pharmaceutically acceptable salt of each thereof, wherein ring A is optionally substituted with 1, 2, 3, or 4 substituents independently selected from the group consisting of halo and C 1 -C 6 alkyl.
13. The compound of claim 1 , or a tautomer thereof, or a pharmaceutically acceptable salt of each thereof, wherein ring B is pyridinyl optionally substituted with one substituent selected from the group consisting of halo, C 1 -C 6 alkyl, COR 15 , and COOR 15 ; wherein R 15 is C 1 -C 6 alkyl optionally substituted with halo.
14. The compound of claim 1 , or a tautomer thereof, or a pharmaceutically acceptable salt of each thereof, wherein ring B is pyridinyl.
15. The compound of claim 4 , or a tautomer thereof, or a pharmaceutically acceptable salt of each thereof, wherein ring B is pyridinyl.
16. A pharmaceutical composition comprising a compound of claim 4 , or a tautomer thereof, or a pharmaceutically acceptable salt of each thereof, and at least one pharmaceutically acceptable excipient.
17. A pharmaceutical composition comprising a compound of claim 8 , or a tautomer thereof, or a pharmaceutically acceptable salt of each thereof, and at least one pharmaceutically acceptable excipient.
18. A method for increasing oxygen affinity of hemoglobin S in a subject, the method comprising administering to a subject in need thereof a compound of claim 4 , or a tautomer thereof, or a pharmaceutically acceptable salt of each thereof.
19. A method for treating sickle cell disease, the method comprising administering to a subject in need thereof a compound of claim 4 , or a tautomer thereof, or a pharmaceutically acceptable salt of each thereof.
20. A method for increasing oxygen affinity of hemoglobin S in a subject, the method comprising administering to a subject in need thereof a compound of claim 8 , or a tautomer thereof, or a pharmaceutically acceptable salt of each thereof.
21. A method for treating sickle cell disease, the method comprising administering to a subject in need thereof a compound of claim 8 , or a tautomer thereof, or a pharmaceutically acceptable salt of each thereof.